| ALX Oncology Holdings is a holding company. Through its subsidiaries, Co. is a clinical stage immuno-oncology company. Co.'s primary program is a checkpoint inhibitor designed to have an affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. Co.'s primary product candidate, ALX148, is a CD47 blocking biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes, acute myeloid leukemia, head and neck squamous cell carcinoma, gastric/gastric/gastroesophageal junction and breast cancer. We show 7 historical shares outstanding datapoints in our ALXO shares outstanding history coverage, used to compute ALXO market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ALXO market cap history over the course of time is important for investors
interested in comparing ALXO's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ALXO versus a peer is one thing; comparing
ALXO market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ALXO can fluctuate over the course of history.
With this page we aim to empower investors researching ALXO by allowing them to research the ALXO market cap history.